Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > BUSINESS
BUSINESS
- CMIC Subsidiary to Expand Non-Clinical Operations by Business Transfer
May 29, 2012
- Chugai Files NDA for Breast Cancer Treatment Pertuzumab in Japan
May 29, 2012
- Sanofi-aventis Applies for Switch OTC Allegra, PAFSC Committee to Review on June 7
May 28, 2012
- 26 TSE 1st-Section Drug Makers Post Overall Decline in Sales, Profits for FY2011: JPMA
May 28, 2012
- Meiji Seika Pharma Aims to Increase No. of MRs to 900 as Soon as Possible
May 28, 2012
- Nearly 30% Use “Only Neostigmine”: Neuromuscular Antagonists Usage Survey
May 28, 2012
- US Subsidiary of DSP Settles COPD Drug Patent Infringement Suit
May 28, 2012
- DPP-4 Inhibitors Gain Traction, Boosting Diabetes Market by 15.5%: IMS Japan
May 25, 2012
- Zeria Projects 19% Increase in Asacol Sales to 12.2 Billion Yen in FY2012
May 25, 2012
- Japanese Ethical Drug Market Expands by 5.5% to 9.5348 Trillion Yen: IMS Japan
May 25, 2012
- Takeda Files MAA for Alogliptin in Europe
May 25, 2012
- National Cancer Center, Daiichi Sankyo Conclude Comprehensive Joint Research Agreement for Cancer Drug Discovery
May 24, 2012
- RIKEN and Takeda Open Collaboration Center for Developing Drug Discovery Technology for CNS Diseases
May 24, 2012
- Daiichi Sankyo Completes Patient Recruitment in Overseas PIII Trial of ARQ 197 for NSCLC
May 24, 2012
- Xarelto No. 1, Prazaxa Ranks 2nd in Call Frequency in HP Market: Rep Track April Survey
May 24, 2012
- Meiji HD Targets Pharmaceuticals Segment Sales at 140 Billion Yen in FY2014
May 23, 2012
- Four Major Listed Dispensing Pharmacies Post Record Performance in FY2011
May 23, 2012
- Myslee Is Most Prescribed Insomnia Drug: Survey
May 23, 2012
- AnGes MG to Allocate Shares Worth 200 Million Yen to Shionogi to Develop NF-κB Decoy Oligo
May 23, 2012
- 11 Leading Foreign-Affiliated Drug Makers Report 12% Growth in Sales in 2011 Driven by New Drugs
May 23, 2012
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…